fashion -WSS

fashion

author：focus 2025-10-01 15:27:59 - browse：23

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： White House calls on federal agencies to crack down on AI abuses

WSS

VC firm General Catalyst wants to buy a health system

Study: New antibiotic targets gonorrhea as well as last existing drug

Will General Catalyst be the first of many hospital takeovers?

Ambulance rides for just $100? Advisers want major billing fixes

The Sacklers, horror, and ‘The Fall of the House of Usher’

Sana to lay off nearly a third of staff, de

knowledge

fashion

entertainment

What does generative AI mean for health care? We asked experts

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Walensky prepares to leave CDC — and Congress — behind

FDA approves Recor Medical high blood pressure device

Medicare proposal to cover medical devices draws a mixed reaction

Diversify hospital leadership teams to protect BIPOC patient health

United colonoscopy coverage change 'may cost lives,' doctors say

Abortion clinic in Cancun will cater to Americans

In age of alternative facts, a scholarly course on calling out crap

More doctors should go into startup world

focus

Chemotherapy drug shortage eases slightly but still widespread

Was Amgen transparent enough on FDA's concern on cancer drug?

10 million people disenrolled from Medicaid over past six months

Sanofi CEO defends move to abandon profit guidance, boost research

A virus, fished out of a lake, may have saved a man’s life

Stroke deaths set to near 10 million globally by 2050

focus

leisure time

Wikipedia

hotspot